SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13D-2(b)
(Amendment No.____________)(1)
VioQuest Pharmacueticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
927625 10 3
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2004
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-(c)
[_] Rule 13d-1(d)
----------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 927625 10 3 13G Page 2 of 5 Pages
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Xumu Zhang, Ph.D.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
--------------------------------------------------------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES 2,780,775
-----------------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 0
-----------------------------------------------------------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 2,780,775
-----------------------------------------------------------------
PERSON 8. SHARED DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,780,775
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
15.5%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
CUSIP No. 927625 10 3 13G Page 3 of 5 Pages
--------------------------------------------------------------------------------
Item 1(a). Name of Issuer:
VioQuest Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
Item 1(b). Address of Issuer's Principal Executive Offices:
7 Deer Park Drive, Suite #, Monmouth Junction, NJ 08852
--------------------------------------------------------------------------------
Item 2(a). Name of Person Filing:
Xumu Zhang, Ph.D.
--------------------------------------------------------------------------------
Item 2(b). Address of Principal Business Office, or if None, Residence:
7 Deer Park Drive, Suite #, Monmouth Junction, NJ 08852
--------------------------------------------------------------------------------
Item 2(c). Citizenship:
USA
--------------------------------------------------------------------------------
Item 2(d). Title of Class of Securities:
Common Stock, $.01 par value
--------------------------------------------------------------------------------
Item 2(e). CUSIP Number:
927625 10 3
--------------------------------------------------------------------------------
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or
(c), Check Whether the Person Filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Exchange
Act.
(b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange
Act.
(d) [_] Investment company registered under Section 8 of the Investment
Company Act.
(e) [_] An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act;
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act;
(j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
CUSIP No. 927625 10 3 13G Page 4 of 5 Pages
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
2,780,775 (includes 162,513 shares issuable upon exercise of an
option which is currently vested)
--------------------------------------------------------------------
(b) Percent of class:
15.5%
--------------------------------------------------------------------
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 2,780,775
---------------------
(ii) Shared power to vote or to direct the vote: 0
------------------
(iii) Sole power to dispose or to direct the disposition of:
2,780,775
---------
(iv) Shared power to dispose or to direct the disposition of:
0
---------
--------------------------------------------------------------------------------
Item 5. Ownership of Five Percent or Less of a Class.
N/A
--------------------------------------------------------------------------------
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
N/A
--------------------------------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.
N/A
--------------------------------------------------------------------------------
Item 8. Identification and Classification of Members of the Group.
N/A
--------------------------------------------------------------------------------
Item 9. Notice of Dissolution of Group.
N/A
--------------------------------------------------------------------------------
Item 10. Certifications.
(b) The following certification shall be included if the statement is
filed pursuant to Rule 13d-1(c):
"By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in
any transaction having such purpose or effect."
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 10, 2005 /s/ Xumu Zhang
---------------------------
Xumu Zhang